natgillin/translations-raw huggingface dataset:
is hydrogen, C1 to C12 alkyl, phenyl unsubstituted or substituted by C1 to C12 alkyl or COR6 acyl group; R6 being hydrogen, C1 to C12 straight chain or branched alkyl, phenyl or benzoyl, respectively, unsubstituted or substituted by C1 to C12 alkyl, or any group leading to hydroxyl upon biological metabolization or chemical deprotection, wherein said compound is 4-hydroxytestosterone or its salts or esters. 
Ra je vodik, Ci do C,> alkil, fenil koji nije supstituiran ili je supstituiran s C; do Cy2 alkilnom ili COR; acilnom skupinom; R; je vodik, C, do C,» nerazgranati ili razgranati alkil, fenil ili benzoil, koji odgovarajuće nije supstituiran ili je supstituiran s Cy do Cy alkilnom, ili bilo kojom skupinom koja se pretvara u hidroksilnu biološkim metaboliziranjem ili kemijskim uklanjanjem zaštite, gdje je navedeni spoj 4-hidroksitestosteron, ili njegove soli ili esteri.
RD1 is attached to carbon number 3" or 4"; 
R'' je vezan na ugljik broj 3" ili 4";
non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi's sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors. 
nesitnostaničnog karcinoma pluća, sitnostaničnog karcinoma pluća), karcinoma jajnika, karcinoma grlića maternice, karcinoma želuca, karcinoma endometrija, karcinoma jednjaka, karcinoma glave i vrata, melanoma, neuroendokrinog karcinoma, karcinoma CNS-a, tumora mozga (npr., glioma, anaplastičnog oligodendroglioma, adultnog glioblastoma multiforme, 1 adultnog anaplastičnog astrocitoma), karcinoma kosti, sarkoma mekog tkiva, retinoblastoma, neuroblastoma, peritonealnih efuzija, malignih pleuralnih efuzija, mezotelioma, Wilms-ovih tumora, trofoblastičnih neoplazmi, hemangiopericitoma, Kaposi-jevih sarkoma, miksoidnih karcinoma, karcinoma okruglih stanica, karcinoma skvamoznih stanica, karcinoma skvamoznih stanica jednjaka, oralnih karcinoma, karcinoma adrenalnog korteksa i tumora koji proizvode ACTH.
Headset apparatus according to claim 7 in which the attachment means is connected to the further attachment means. 
Slušalice prema zahtjevu 7, naznačene time, da je navedeni priključni uređaj spojen na dodatni priključni uređaj.
The dose capable of reducing the production of the conditioned response by 50% (ED50) compared to basal values is 1.43 mg/kg (5.05 umol/kg) (Table 2). 
Doza koja je sposobna smanjiti nastanak uvjetovanog odgovora za 50 % (EDs9) u usporedbi s osnovnim vrijednostima je 1,43 mg/kg (5,05 umol/kg) (Tablica 2).
The method of claim 13, wherein said surgical procedure is a laser treatment. The method of claim 13, wherein said therapeutically effective amount of an a adrenergic receptor agonist is administered prior to, during, or after said surgical procedure. 
Agonist za uporabu u skladu sa zahtjevom 1, naznačen time što purpura je purpura uzrokovana kirurškim postupkom, te pri čemu se agonist alfa adrenergijskog receptora primjenjuje prije kirurškog zahvata, tijekom kirurškog zahvata, nakon kirurškog zahvata, ili njihovih kombinacija.
A pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable excipient or carrier is: water-for-injection, aqueous saline solution, aqueous glucose solution, saline for injection/infusion, glucose for injection/infusion, Ringer's solution, or lactated Ringer's solution. 
Farmaceutski sastav prema zahtjevu 11 1li 12, naznačen time, da nadalje sadrži: vodu za injekciju, vodenu solnu otopinu, vodenu otopinu glukoze, vodenu otopinu soli za injekciju/infuziju, glukozu za injekciju/infuziju, Ringer-ovu otopinu, ili mliječnu Ringer-ovu otopinu.
The analysis cartridge system of claim 8 wherein in the breath analysis cartridge the breath chamber is sealed from the fluid chamber when the filter assembly is in the first position, and wherein in the fluorescence analysis cartridge the upper chamber is sealed from the fluid chamber when the filter assembly is in the first position. 
Sustav kazete za analizu prema zahtjevu 8, naznačen time, da je u kazeti za analizu daha komora za dah zabrtvljena prema fluidnoj komori kada je filterski sklop u prvoj poziciji, te time, da je u fluorescentnoj kazeti za analizu gornja komora zabrtvljena prema fluidnoj komori kada je filterski sklop u prvoj poziciji.
The method of claim 26, wherein the pores are sized at about 0.2 µm or about 0.22 µm. 
Metoda prema patentnom zahtjevu 16, naznačena time da su pore veličine 0,2 um ili 0,22 um.
a heavy chain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:88, or/and 
jaki lanac koji ima identitet sekvence barem 90% od aminokiselinske sekvence od SEQ ID NO:88, i/ili
The present invention is based on the development of a process for the cultivation of cells in a cell culture medium that is free from animal serum-derived components and at the same time highly effective for cell growth and maintenance of mammalian cell culture. 
Prikazani se izum temelji na razvoju procesa za uzgoj stanica u mediju za kulturu stanica koji ne sadrži komponente podrijetlom iz animalnog seruma i koji je u isto vrijeme visoko učinkovit za stanični rast i održavanje kulture stanica sisavaca.
The compound for use of claim 1, wherein the disease or disorder is glioblastoma multiforme. A pharmaceutical composition comprising a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for use in the treatment of a disease or disorder which is selected from genitourinary cancer, glioblastoma, small bowel cancer, and breast cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je višestruki oblik glioblastoma, Farmaceutski sastav, naznačen time, da obuhvaća spoj koji ima strukturu prikazanu u zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljiv nosač, pri čemu se on upotrebljava u liječenju bolesti ili poremećaja koja/i je odabran/a od sljedećih: genitalno-urinarni rak, glioblastom, rak tankog crijeva i rak dojke.
o Is free of amino acids other than histidine or comprises one or more amino acids other than histidine in a (collective) concentration of at most 0.001 mM; 
je ili bez aminokiselina osim histidina ili sadrži jednu ili više aminokiselina osim histidina u (kolektivnoj) koncentraciji od najviše 0,1 mM; i
Plastics materials can be grinded up, and the resulting granulate can be used in production of new plastics materials. 
Plastični materijali se mogu samljeti, čime se dobije granulat koji se može upotrijebiti za proizvodnju novih plastičnih materijala.
An isolated antibody according to claim 1 for use as a medicament. An isolated antibody according to claim 1 for use in treating hematological cancer, wherein said hematological cancer is selected from the group consisting of multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myeloid leukemia, B-cell lymphoma, and Burkitt's lymphoma. 
Izolirano protutijelo za uporabu u liječenju raka prema zahtjevu 9 naznačeno time da navedeni rak je hematološki rak i odabran je iz skupine koju čine multipli mijelom, kronična limfoblastična leukemija, kronična limfocitna leukemija, leukemija stanica plazme, akutna mijeloidna leukemija, kronična mijeloidna leukemija, limfom B stanica, i Burkittov limfom.
an heteroaryl group selected from substituted and unsubstituted pyridine, pyrimidine, pyrrole, thiophene, indole, thiazole, oxazole; 
heteroaril skupine izabrane između supstituiranog ili nesupstituiranog piridina, pirimidina, pirola, tiofena, indola, tiazola, oksazola;
repeating the conveying and dropping process so that multiple wood pieces are stacked in the same orientation in the measuring compartment; and, when a required amount of stacked wood is within the measuring compartment, dropping the stacked wood pieces into a packing area. 
ponavljanju postupka transportiranja i ispuštanja, tako da se više komada drva naslaže u istoj orijentaciji u odjeljku za mjerenje (12); i kada je tražena količina naslaganog drva u odjeljku za mjerenje (12), ispuštanju naslaganih komada drva u područje za pakiranje (14).
The mixture was stirred at room temp for 30 min. 
Smjesa je miješana na sobnoj temperaturi 30 minuta.
A Mycobacterium cell which is urease-deficient and which comprises at least one recombinant nucleic acid molecule encoding a phagolysosomal escape peptide or polypeptide. The cell of claim 16, which comprises at least one further recombinant nucleic acid molecule encoding a peptide or polypeptide capable of eliciting an immune response in a mammal. The cell of claim 16 which is a Mycobacterium bovis cell. 
Stanica Mycobacterium, naznačena time što je oskudna ureazom i obuhvaća najmanje jednu rekombinantnu molekulu nukleinske kiseline koja kodira peptid ili polipeptid za bijeg iz fagolizosoma. Stanica prema zahtjevu 16, naznačena time što obuhvaća najmanje jednu dodatnu rekombinantnu molekulu nukleinske kiseline koja kodira peptid ili polipeptid sa sposobnošću izazivanja imunog odgovora kod sisavca, Stanica prema zahtjevu 16, naznačena time što je to stanica Mycobacterium bovis.
A compound selected from the group consisting of: or a pharmaceutically acceptable salt or an isomer thereof. 
Spoj prema zahtjevu 1 odabran iz skupine koja se sastoji od: Ii pe \
Preferably the pathological disorder is rheumatoid arthritis or systemic lupus erythematosus (SLE). 
Antitijelo ili farmaceutski sastav prema zahtjevu 16 za spomenutu upotrebu, pri čemu je patološki poremećaj reumatoidni artritis.
In certain embodiments, R4 and R5 together are a chiral moiety, and the compound of formula (I) present in the composition has a diastereomeric ratio of at least about 96:4 at the carbon atom bearing R1, R2, and R3, relative to a chiral center in the R4—R5 chiral moiety. 
Kompozicija prema patentnom zahtjevu 20, gdje, atom ugljika za koji su vezani R!, R* i Ri, je hiralni centar, koji ima diastereomerni odnos od najmanje 96:4, u odnosu na hiralni centar u R*-R? hiralnoj grupi.
The pharmaceutical composition of any one of claims 1-4 for use in reducing or preventing pain in a mammal by modulating TRPC4 activity, wherein the pain is selected from acute, chronic, neuropathic, nociceptive and visceral pain, or a combination thereof. 
Farmaceutski pripravak koja sadrži 4-metil-2-piperidin-1-il-kinolin koji ima formulu za uporabu u liječenju ili prevenciji bola kod sisavaca moduliranjem aktivnosti TRPC4, pri čemu je bol odabran između akutne, kronične, neuropatske, nociceptivne i visceralne boia, ili njihove kombinacije.
Preferably, a negatively charged amino acid residue is introduced by substitution in position 34, e.g. A34E or A34D. 
Varijanta iz zahtjeva 4, naznačena time, da je negativno nabijen amino kiselinski ostatak bio uveden supstitucijom u položaju 34.
In still other embodiments, V is —CH2— or SO2, and R8 is an optionally substituted group selected from: 
HR P20090572 TI i) -V-R*, gdje je V jednako i R* je grupa izabrana od slijedećih:
Recombinant FSH (rFSH) including a2,3- and a2,6-sialylation wherein 20% to 90% of the total sialylation is a2,3-sialylation; wherein the recombinant FSH has a sialic acid content [expressed in terms of a ratio of moles of sialic acid to moles of protein] of 8 mol/mol to 15 mol/mol. 
Farmaceutski pripravak koji sadrži rFSH uključujući 02,3-sialilaciju i 02,6-sialilaciju gdje 60% ili više od ukupne sialilacije je 02,3-sialilacija i od 5 do 40% od ukupne sialilacije je 02,6-sialilacija; te ima sadržaj sijalinske kiseline [izražen terminom omjera molova sijalinske kiseline prema molovima proteina] od 10 mol/mol do 16 mol/mol.
The antibody according to claim 9 where the antibody is a monoclonal, multi-valent, multi-specific, humanized or chimeric antibody, single chain antibody, Fab fragment, Fab' fragment, F(ab')2 fragment or an epitope-binding fragment thereof. 
Neutralizirajuće antitijelo prema patentnom zahtjevu 4, naznačeno time da je fragment antitijela Fab, Fab', F(ab')2, scFv ili epitopska veza fragmenta iste.
A monoclonal antibody that binds to the polypeptide of any one of claims 1 to 5 or to a portion of human sclerostin of claim 6 or 7 and has a binding affinity for human sclerostin of less than or equal to 1 x 10-10 M. 
Monoklonsko protutijelo koje se veže za polipeptid iz patentnog zahtjeva 2, naznačen time, da se veže za humani sklerostin s disocijacijskom konstantom manjom ili jednakom od 1 x 10-9 M kako je izmjereno površinskom plazmonskom rezonancijom; te povećava barem jednu formaciju kosti, mineralnu gustoću kosti, mineralni sastav kosti, koštanu masu, kvalitetu kosti i jačinu kosti kod sisavca.
A nucleic acid encoding the polypeptide of any of claims 1 to 4, particularly a nucleic acid comprising or consisting of a nucleic acid sequence of SEQ ID NO: 26, wherein said nucleic acid is optionally comprised in a vector. 
Nukleinska kiselina koja kodira polipeptid sukladno bilo kojem patentnom od zahtjeva 1 do 4, posebno nukleinska kiselina koja sadrži ili se sastoji sekvence nukleinske kiseline iz SEQ ID NO: 26, gdje je navedena nukleinska kiselina opciono sadržana u vektoru.
Composition according to claim 19, wherein the biocide with one or more aldehyde groups is selected from the group comprising formaldehyde, acetaldehyde, glyoxal, glutaraldehyde, 2-propenal, phthalic dialdehyde and mixtures thereof, and preferably is formaldehyde, glutaraldehyde or a mixture thereof. 
Sastav u skladu s patentnim zahtjevom 18, pri čemu je biocid s jednom ili više aldehidnih grupa odabran iz grupe koja obuhvaća formaldehid, acetaldehid, glioksal, glutaraldehid, 2-propenal, ftalni dialdehid i njihove smjese, i poželjno je formaldehid, glutaraldehid ili njihova smjesa.
The solution of claim 2, wherein the zinc chelator is ethylenediaminetetraacetic acid (EDTA). 
Formulacija prema zahtjevu 5, naznačena time da je kelator cinka etilendiamintetraoctena kiselina (EDTA).
The crystalline form of Febuxostat, designated Form F2, according to claim 5, characterized by a solid-state 13C NMR spectrum with signals at 112.3, 163.9, 168.8.±0.2 ppm. 
Kristalni oblik febuksostata, označen kao Oblik F2, u skladu s patentnim zahljevom 6, naznačen time što je za njega karakterističan uzorak difrakcije rendgenskih zraka na prahu koji je uglavnom onakav kako je opisano na
The method of claim 1, wherein the amount of microparticles in the composition is 30-40% w/w of the total composition. 
Smjesa iz patentnog zahtjeva 1 ili 2, naznačena time, da je težina mikročestica u rasponu od 30 - 40 % t/t ukupne smjese.
The recombinant RhCMV or HCMV vector of any one of claims 1-9, or the composition of claim 10, for use in a method of treating a subject with an infectious disease, wherein the infectious disease is caused by human immunodeficiency virus (HIV). 
Rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-9, ili pripravak prema zahtjevu 10, naznačen time da je za uporabu u postupku liječenja subjekta sa zaraznom bolesti, pri čemu je zarazna bolest uzrokovana virusom humane imunodeficijencije (HIV).
Method according to claim 13, whereby the products (20) are transported by means of a method according to claim 12, whereby use is also made of the combination during storage and whereby the combination, during the transfer from a use during transport to a use during storage or vice versa, is moved from a storage location to the vehicle or vice versa, whereby the transport box (1) or transport boxes (1) that are on the cooling device (14) stay in this position during the transfer. 
Postupak u skladu s patentnim zahtjevom 13, pri čemu se proizvodi (20) transportiraju pomoću postupka u skladu s patentnim zahtjevom 12, pri čemu se upotreba također može primijeniti od kombinacije tijekom skladištenja, 1 pri čemu kombinacija tijekom transfera iz upotrebe tijekom transporta u upotrebu tijekom skladištenja ili obrnuto se premješta sa lokacije skladištenja u vozilo 1 obrnuto, kod čega transportna kutija (1) ili transportne kutije (1) koje se nalaze u uređaju za hlađenje (14) tijekom prijenosa ostaju u tom položaju.
These objects are achieved in accordance with the invention with the characteristics listed in appended independent claim 1. 
Ovi se ciljevi, sukladno Izumu, postižu putem odlika navedenih u privijenom neovisnom patentnom zahtjevu 1.
A compound for use according to claim 18 wherein the disorder mediated by inappropriate PI3-kinase activity is COPD. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze COPD.
Reactions carried out under microwave conditions were performed in a SmithSynthesizer from Personal Chemistry operating at 2450 MHz. 
Reakcije provedene u mikrovalnim uvjetima izvršene su na SmithSynthesizeru proizvođača Personal Chemistry, koji radi na 2450 MHz.
The modified sulfamidase according to embodiment 1, having a relative content of natural glycan moieties of around 25 % of the content of natural glycan moieties in unmodified recombinant sulfamidase. 
Modificirana sulfamidaza sukladno patentnom zahtjevu 1, ima relativan sadržaj preostalih nedirnutih dijelova prirodnog glikana od oko 25 % od sadržaja dijelova prirodnog glikana u nemodificiranoj rekombinanntnoj sulfamidazi.
The combined drugs could thus be administered once a day. Particularly preferred LABAs are formoterol, salmeterol and GSK-597901, GSK-159797, KUL-1248, TA-2005 and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Poželjniji kortikosteroidi sukladno predmetnom izumu su: budesonid, beklometazon dipropionat, mometazon furoat, ciklesonid, triamcinolon, triamcinolon acetonid, triamcinolon heksa-acetonid i flutikazon propionat, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i njihovih smjesa te adicijskih soli s farmakološki kompatibilnim kiselinama.
An information card as claimed in claim 19, wherein the information card and the second information card comprise different information. 
METODA ZA PRIČVRŠĆIVANJE INFORMACIJSKE KARTICE ZA PROIZVOD U BLISTER PAKIRANJU, INFORMACIJSKA KARTICA I SISTEM KORIÅ TENJA INFORMACIJSKE KARTICE HR P20160213 T1
reaction of a compound of formula (X) wherein R2 is as defined in formula (I), R3 is H or a suitable protecting group and X is a leaving group such as halide or triflate; with an acetylenic compound of formula (IX) wherein R1 is as defined in formula (I); or 
H Q (X) HR P20100020 T1 gdje je R* kako je definirano u formuli (1), R* je H ili prikladna zaštitna skupina, a X je odlazna skupina poput halida ili triflata; sa acetilenskim spojem formule (IX) oo
an antibiotic, polyclonal gamma-globulin, probiotic agent or C . difficile vaccine; vancomycin, metronidazole, bacitracin, Saccharomyces boulardii or a toxoid vaccine; or 
Antitijelo, ili njegov dio koji se veže za antigen, prema patentnom zahtjevu 20, naznačeno time što je terapeutsko sredstvo antibiotik, poliklonalni gama-globulin, probiotsko sredstvo ili C. difficile vakcina.
An isolated mutant of a wild-type staphylococcal leukocidin subunit polypeptide comprising SEQ ID NO: 5, 6 or 15, wherein the mutant staphylococcal leukocidin subunit polypeptide comprises an amino acid substitution at a position corresponding to K97 of SEQ ID NO: 6 which reduces toxicity of the mutant leukocidin subunit relative to the corresponding wild-type leukocidin subunit; 
Izolirani mutant polipeptida divljeg tipa stafilokokne podjedinice leukocidina koji sadrži SEQ ID NO: 5, 6 ili 15, naznačen time što mutant polipeptida stafilokokne podjedinice leukocidina sadrži aminokiselinsku supstituciju na položaju koji odgovara K97 u SEQ ID NO: 6 što smanjuje toksičnost mutanta podjedinice leukocidina u odnosu na odgovarajuću podjedinicu divljeg tipa leukocidina;
A pharmaceutical tablet in accordance with any one of the preceding claims having (a) a cracking force of at least 110 N, preferably 120 N, more preferably 130 N, and even more preferably 140 N, when subjected to an indentation test; (b) a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test; and (c) capable of resisting a work of at least 0.06 J without cracking. 
Farmaceutska tableta prema prethodnim zahtjevima naznačena time da ima (a) silu loma od najmanje 110 N, poželjno 120 N, poželjnije 130 N, te najpoželjnije 140 N, kada je podvrgnuta indentacijskom testu; (b) dubinu prodiranja s razmakom pukotine od najmanje 1.0 mm, poželjno 1.2 mm, poželjnije 1.4 mm, te najpoželjnije 1.6 mm, kada je podvrgnuta indentacijskom testu; te (c) da se može oduprijeti radu od najmanje 0.06 J bez loma. S Temperatura
In the preparation of acid addition salts, preferably such acids are used which form therapeutically acceptable salts. 
Tijekom pripreme kiselinsko adicijskih soli poželjno su rabljeni takve soli koje oblikuju terapeutski prihvatljive soli.
The system as claimed in claim 7 wherein a first tip of the first electrode (2b.1) is planar and a second tip of the second electrode (2b.2) is planar. 
Sustav prema zahtjevu 7, pri čemu su prvi vrh prve elektrode (2b.1) i drugi vrh druge elektrode (2b.2) ravni.
a transmission power value of the A-SRS received in response to the TPC command transmitted in a non-specific subframe is based on a first accumulation value of the TPC command, and 
Postupak radio komunikacije sukladno zahtjevu 6, sadržeći, postavljanje prve akumulacijske vrijednosti, prije nego što se podvrgne navedenom ažuriranju s TPC naredbom, na nulu nakon navedene inicijacije.
where L1 is a leaving group, in the presence of a base; or 
II u prisutnosti di(1H-imidazol-2-il)metanetiona i baze; ili
The composition according to claim 11, wherein the amount of the film-coating is about 3 weight percent. 
Pripravak u skladu s patentnim zahtjevom 11, pri čemu je količina filmskog premaza oko 3 masena postotka.
A polypeptide for use according to any one of claims 4 to 7, wherein said polypeptide is provided in a pharmaceutical composition comprising said polypeptide and at least one pharmaceutically acceptable excipient; said modified FIX polypeptide being present in the pharmaceutical composition in an amount suitable for administration in a daily dosage comprised between 0.1 µg/kg and 400 µg/kg body weight. 
Polipeptid za uporabu, sukladno navedenim zahtjevima 4-7, naznačen time, što je navedeni polipeptid osiguran u farmacetskom sastavu koji sadrži navedeni polipeptid i najmanje jedan farmaceutski prihvatljiv ekscipijens:; navedeni modificirani FIX polipeptid prisutan je u farmaceutskom pripravku u količini prikladnoj za primjenu u dnevnoj dozi izmedju 0.! me/kg 1 400 mg/kg tjelesne težine.
The composition for use in the treatment according to claim 40, wherein the a2B1 integrin-associated disorder is selected from multiple sclerosis, rheumatoid arthritis, optical neuritis and spinal cord trauma. 
Oblik za uporabu u liječenju prema zahtjevu 40, gdje se poremećaj povezan s a2B1 integrinom izabire između multiple skleroze, reumatoidnog artritisa, optičkog neuritisa i traume leđne moždine.
As seen in Table 1, this compound binds PPARY with high affinity (IC50 = 30 nM) and to PPARa with relatively lower affinity (IC50 = 360). 
Kao što se vidi u Tablici 1, ovaj spoj veže se na PPARy s visokim afinitetom (ICs, = 30 nM), te na PPARa s relativno nižim afinitetom (ICsg = 360).
Preferably also, the base used in the process according to embodiment 2) or 3) will be selected from the group consisting of NaOH, KOH and potassium tert-butylate. 
Postupak prema zahtjevu 2 ili 3, naznačen time, da je lužina odabrana iz skupine koju čine NaOH, KOH i kalijev tert-butilat.